USFDA observations at Bachupally facility
USFDA issued a post-action letter for observations at the Bachupally biologics facility, potentially delaying rituximab and denosumab approvals.
high · management_commentary
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Lenalidomide revenue cliff from Q4
Management advised assuming zero lenalidomide revenue from Q4 FY26, which will impact overall revenue and margins.
high · management_commentarySemaglutide pricing pressure in Canada
Management acknowledged that semaglutide pricing may be at the lower end of the $20-70 range due to competition, including Novo Nordisk's own generic.
medium · analyst_questionBiosimilar denosumab delay in US
CRL for denosumab from Alvotech facility may push US approval to Q2 FY27 or later, impacting biosimilar revenue expectations.
medium · analyst_question